P1-12-02: Patient-Reported Outcomes (PROs) from a Randomized Phase II Study (TDM4450g/BO21976) of Trastuzumab Emtansine (T-DM1) vs Trastuzumab Plus Docetaxel (HT) in Previously Untreated HER2−Positive Metastatic Breast Cancer (MBC).

Phase Ii ◽

Patient Reported Outcomes ◽

Phase Ii Study ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Randomized Phase Ii ◽

Patient Reported

Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer

Breast Cancer Research ◽

10.1186/bcr3661 ◽

2014 ◽

Vol 16 (3) ◽

Cited By ~ 30

Author(s):

Edith A Perez ◽

Sara A Hurvitz ◽

Lukas C Amler ◽

Kirsten E Mundt ◽

Vivian Ng ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Expression ◽

First Line ◽

Her2 Positive ◽

A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with Her2-positive metastatic breast cancer - E-Vita -

Annals of Oncology ◽

10.1093/annonc/mdw365.52 ◽

2016 ◽

Vol 27 ◽

pp. vi85

Author(s):

J. Bischoff ◽

J. Barinoff ◽

C. Mundhenke ◽

D. Bauerschlag ◽

S.D. Costa ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Her2 Positive ◽

Abstract PD3-09: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2- positive metastatic breast cancer: Results from the EORTC 75111- 10114 ETF/BCG randomized phase II study

10.1158/1538-7445.sabcs17-pd3-09 ◽

2018 ◽

Author(s):

H Wildiers ◽

K Tryfonidis ◽

L dal Lago ◽

P Vuylsteke ◽

G Curigliano ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Older Patients ◽

Phase Ii Study ◽

Metastatic Breast ◽

Metronomic Chemotherapy ◽

Her2 Positive ◽

Abstract P6-17-23: Randomized phase II study of lapatinib plus vinorelbine versus vinorelbine in patients with HER2 positive metastatic breast cancer progressed after lapatinib and trastuzumab treatment

10.1158/1538-7445.sabcs18-p6-17-23 ◽

2019 ◽

Author(s):

SH Sim ◽

IH Park ◽

KH Jung ◽

S-B Kim ◽

J-H Ahn ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Her2 Positive ◽

Trastuzumab Treatment ◽

Abstract P2-15-04: Patient-reported outcomes in a randomized, optimal dose finding, phase II study of triweekly nab-paclitaxel in patients with metastatic breast cancer (the ABROAD study)

10.1158/1538-7445.sabcs19-p2-15-04 ◽

2020 ◽

Author(s):

Hiroaki Kato ◽

Fumikata Hara ◽

Masahiro Kitada ◽

Masato Takahashi ◽

Yuichiro Kikawa Yuichiro Kikawa ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Patient Reported Outcomes ◽

Phase Ii Study ◽

Metastatic Breast ◽

Optimal Dose ◽

Dose Finding ◽

Patient Reported

A phase II study of eribulin in patients with HER2-negative, metastatic breast cancer: Evaluation of efficacy, toxicity, and patient-reported outcomes.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps1138 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS1138-TPS1138

Author(s):

Otto Metzger-Filho ◽

Nancy U. Lin ◽

Steven E. Come ◽

Thomas H. Openshaw ◽

Bryan P. Schneider ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Patient Reported Outcomes ◽

Phase Ii Study ◽

Metastatic Breast ◽

Patient Reported

5001 ORAL Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (H+T) in Previously-untreated HER2-positive Metastatic Breast Cancer (MBC): Primary Results of a Randomized, Multicenter, Open-label Phase II Study (TDM4450g/BO21976)

European Journal of Cancer ◽

10.1016/s0959-8049(11)71443-5 ◽

2011 ◽

Vol 47 ◽

pp. S330 ◽

Cited By ~ 25

Author(s):

S. Hurvitz ◽

L. Dirix ◽

J. Kocsis ◽

L. Gianni ◽

J. Lu ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Open Label ◽

Open Label Phase

Safety of Herceptin monotherapy administered on a 3-weekly schedule: Preliminary data from a phase II study in women with HER2-positive metastatic breast cancer

European Journal of Cancer ◽

10.1016/s0959-8049(02)80299-4 ◽

2002 ◽

Vol 38 (11) ◽

pp. S95

Author(s):

J Baselga

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Preliminary Data ◽

Phase Ii Study ◽

Metastatic Breast ◽

Weekly Schedule ◽

Her2 Positive

SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER+) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer

Annals of Oncology ◽

10.1093/annonc/mdx365.084 ◽

2017 ◽

Vol 28 ◽

pp. v106-v107 ◽

Cited By ~ 3

Author(s):

P. Villagrasa Gonzalez ◽

A. Prat ◽

M. Oliveira ◽

L. de la Pena ◽

X. Gonzalez ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Her2 Positive

232 Final Results of a Phase II Study of the Combination of Oral Vinorelbine (NVBo), Capecitabine (X) and Trastuzumab (H) in HER2-positive Metastatic Breast Cancer (MBC)

European Journal of Cancer ◽

10.1016/s0959-8049(12)70300-3 ◽

2012 ◽

Vol 48 ◽

pp. S110

Author(s):

L. Petruzelka ◽

V. Ganju ◽

P.F. Conte ◽

N. Tubiana-Mathieu ◽

F. Majois ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Her2 Positive ◽

Oral Vinorelbine